



UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2023 P 3151-4
Program	Step Therapy
Medication	Zilxi (minocycline)
P&T Approval Date	12/2020, 2/2021, 3/2022, 3/2023
Effective Date	6/1/2023; Oxford only: 6/1/2023

1. Background:

Zilxi is a tetracycline-class drug indicated for the treatment of inflammatory lesions of rosacea in adults.

Step therapy programs are utilized to encourage use of lower cost alternatives for certain therapeutic classes. This program requires a member to a trial of lower cost rosacea medications before providing coverage for Zilxi.

2. Coverage Criteria^a:

A. Zilxi will be approved based upon the following criterion:

1. History of failure, contraindication, or intolerance to **one** of the following topical therapies (document drug, date of trial, and reason for therapeutic failure, contraindication, or intolerance):
 - a. azelaic acid (Finacea)
 - b. Soolantra

Authorization will be issued for 12 months.

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits and/or Notification may be in place.

4. References:

1. Zilxi [package insert]. Bridgewater, NJ: Vyne Pharmaceuticals Inc; September 2022.
2. Rosacea: Diagnosis and Treatment. *American Family Physician*. 2015 Aug 1;92(3):187-196
3. Rosacea Medical Management Guidelines. *American Acne & Rosacea Society*. 2014 Mar;93(3):134-138

Program	Step Therapy – Zilxi (minocycline)
Change Control	
12/2020	New program
2/2021	Updated criteria to trial of one. Removed metronidazole from step one options.
3/2022	Annual review. Updated references.
3/2023	Annual review. Updated references.